...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urologic oncology >Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?
【24h】

Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?

机译：LHRH激动剂治疗患有前列腺癌的男性患疾病的风险：神话还是事实？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: The traditional assumption of a linear relationship between serum testosterone and prostate cancer growth has been seriously challenged, as overwhelming evidence contradicts its basic principles. Luteinizing hormone releasing hormone (LHRH) agonists are known to cause a peak in serum testosterone level in the initial weeks of treatment, and prevention of the clinical sequelae of testosterone flare by concomitant use of antiandrogens is recommended. Along the present biological concept that there appears to be a limit to the ability of androgens to stimulate prostate cancer growth, termed the saturation model, the use of antiandrogens to prevent this disease flare is questioned. The purpose of this review is to gain historical and modern evidence to provide an objective and up-to-date basis for clinical decision making.
机译：目标：血清睾丸激素与前列腺癌生长之间呈线性关系的传统假设受到了严峻的挑战，因为绝大多数证据都与其基本原理相矛盾。促黄体生成激素释放激素（LHRH）激动剂在治疗的最初几周会导致血清睾丸激素水平达到峰值，因此建议同时使用抗雄激素来预防睾丸激素耀斑的临床后遗症。沿着目前的生物学概念，即被称为饱和模型的雄激素刺激前列腺癌生长的能力似乎是有限的，人们质疑使用抗雄激素来预防这种疾病的发作。这篇综述的目的是获得历史和现代证据，以便为临床决策提供客观和最新的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号